Details of the Drug Reposition

General Information of This Drug (ID: DMUOT9V)

Drug Name
Taxol   DMUOT9V
Synonyms
C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Approved [1]
Breast cancer DIS7DPX1 2C60-2C65 Approved [2]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pancreatic cancer DISJC981 2C10 Phase 3 [3]
------------------------------------------------------------------------------------
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastric adenocarcinoma DISWWLTC 2B72 Phase 2 [4]
Ovarian cancer DISZJHAP 2C73 Phase 2 [4]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)